NZ Immuno-Oncology Research Review Issue 15

In this issue:
  -  Clinical impact of COVID-19 on cancer patients treated with ICIs
  -  Preliminary NCCN recommendations for COVID-19 vaccination
  -  Pretreatment BMI and outcomes in cancer patients treated with ICIs
  -  Low-dose pembrolizumab and nivolumab for relapsed/refractory classical HL
  -  Long-term survival in relapsed/refractory ALL treated with blinatumomab
  -  AFM13 + pembrolizumab in relapsed/refractory HL
  -  Pathophysiology and management of CAR T-cell therapy toxicities
  -  Immune reconstitution and infections following axi-cel for large B-cell lymphoma
  -  Second CD19-targeted CAR T-cell infusions for refractory B-cell malignancies
  -  Ide-cel in relapsed/refractory myeloma

Please login below to download this issue (PDF)